Lung Cancer Clinical Trials in New York

Showing 381-400 of 691 trials

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Unresectable Stage III NSCLC

AstraZeneca40 participantsStarted Apr 2020

Long Beach, California, United States • Santa Ana, California, United States • Englewood, Colorado, United States +15 more locations

TERMINATEDPhase 1< 1 mile

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more

Blueprint Medicines Corporation20 participantsStarted Jan 2022

Boston, Massachusetts, United States • Detroit, Michigan, United States • New York, New York, United States +4 more locations

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Lung Cancer Trials in Other Cities

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Physical Activity Intervention for Lung Cancer Survivors

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

Safety Study of SEA-CD40 in Cancer Patients

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

A Chart Review Study of Adults With Advanced NSCLC

Other Conditions in New York